Successful treatment of infantile refractory bullous pemphigoid with baricitinib

Australas J Dermatol. 2024 Dec;65(8):642-646. doi: 10.1111/ajd.14345. Epub 2024 Jul 19.

Abstract

Infantile bullous pemphigoid (BP) is a rare autoantibody-mediated skin disorder. We report the effective treatment of a 6-month-old infant with BP using baricitinib, a Janus kinase (JAK) inhibitor, after failure with steroids and intravenous immunoglobulin. The patient achieved full remission and discontinued all medications without any relapses. To our knowledge, this is the first case of baricitinib used in an infant with BP.

Keywords: Janus kinase inhibitors; baricitinib; bullous pemphigoid; infant; therapeutics.

Publication types

  • Case Reports

MeSH terms

  • Azetidines* / therapeutic use
  • Humans
  • Infant
  • Janus Kinase Inhibitors / therapeutic use
  • Pemphigoid, Bullous* / drug therapy
  • Purines* / therapeutic use
  • Pyrazoles* / therapeutic use
  • Sulfonamides* / therapeutic use

Substances

  • Azetidines
  • baricitinib
  • Janus Kinase Inhibitors
  • Purines
  • Pyrazoles
  • Sulfonamides